deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT05931367

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)

A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

Sponsor: Eli Lilly and Company

Updated 16 times since 2023 Last updated: Jan 20, 2026 Started: Aug 1, 2023 Primary completion: Nov 14, 2025 Completion: Nov 14, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Obesity and Osteo Arthritis Knee, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 16 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

16 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

Show 11 earlier versions
  1. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  6. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE3

  7. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE3

  8. Nov 2023 — Mar 2024 [monthly]

    Recruiting PHASE3

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  10. Sep 2023 — Oct 2023 [monthly]

    Not Yet Recruiting PHASE3

  11. Aug 2023 — Sep 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .